The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Activation of the cell death program by inhibition of proteasome function
Open accessAbstract
Activation of proteolytic enzymes, including cysteine proteases of the ced-3/ICE family, is a characteristic feature of the apoptotic program. In contrast, the role of the proteasome as the major nonlysosomal machinery to degrade or process proteins by ATP/ubiquitin-dependent proteolysis in this process is less clear. In human leukemic HL60 cells, inhibition of proteasome-mediated proteolysis by specific proteasomal inhibitors leads to the rapid induction of apoptosis as judged by morphological changes as well as by nuclear condensation and DNA fragmentation. HL60 apoptosis is due to activation of CPP32, a member of the ced-3/ICE family of cysteine proteases, and appears to occur independently from ICE activity. HL60 apoptosis is accompanied by an increase in the concentration of the cyclin-dependent kinase inhibitor p27 Kip1 . Labeling of the cells by the TUNEL technique demonstrates that HL60 cells undergoing apoptosis are primarily in the G 1 phase of the cell cycle. Proteasomal activity therefore appears to be required in proliferating, but not in quiescent, HL60 cells for cell survival as well as normal progression through the cell cycle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979
Induction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., & Earnshaw, W. C. (1994) · Nature · doi:10.1038/371346a0 · Cited by 2,562
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Yuan, J. (1993) · Cell · doi:10.1016/0092-8674(93)90485-9 · Cited by 2,483
Mechanisms and Genes of Cellular Suicide
Steller, H. (1995) · Science · doi:10.1126/science.7878463 · Cited by 2,479
Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., & Dixit, V. M. (1995) · Cell · doi:10.1016/0092-8674(95)90541-3 · Cited by 2,367
Cited by
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Advances in Copper Complexes as Anticancer Agents
Santini, C., Pellei, M., Gandin, V., Porchia, M., Tisato, F., & Marzano, C. (2014) · Chemical Reviews · doi:10.1021/cr400135x · Cited by 1,790
Proteasome inhibitors: valuable new tools for cell biologists.
Lee, D. H., & Goldberg, A. L. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01346-4 · Cited by 1,474
Nishitoh, H., Matsuzawa, A., Tobiume, K., Saegusa, K., Takeda, K., Inoue, K., Hori, S., Kakizuka, A., & Ichijo, H. (2002) · Genes & Development · doi:10.1101/gad.992302 · Cited by 1,338
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Proteasome inhibitors: from research tools to drug candidates
Kisselev, A. F., & Goldberg, A. L. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,184
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Development of the Proteasome Inhibitor Velcade™ (Bortezomib)
Adams, J., & Kauffman, M. (2004) · Cancer Investigation · doi:10.1081/cnv-120030218 · Cited by 654
Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
The proteasome: a novel target for cancer chemotherapy
Almond, J., & Cohen, G. (2002) · Leukemia · doi:10.1038/sj.leu.2402417 · Cited by 538
Jana, N. R. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1049 · Cited by 452
The ubiquitin‐proteasome pathway and proteasome inhibitors
Myung, J., Kim, K. B., & Crews, C. M. (2001) · Medicinal Research Reviews · doi:10.1002/med.1009 · Cited by 446
Li, B., & Dou, Q. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070047997 · Cited by 446
20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development
Borissenko, L., & Groll, M. (2007) · Chemical Reviews · doi:10.1021/cr0502504 · Cited by 407
Jung, T., Catalgol, B., & Grune, T. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.04.001 · Cited by 389
The role of the ubiquitin-proteasome pathway in apoptosis
Orlowski, R. Z. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400505 · Cited by 386
Development of the Proteasome Inhibitor PS-341
Adams, J. (2002) · The Oncologist · doi:10.1634/theoncologist.7-1-9 · Cited by 369
Deadly encounter: ubiquitin meets apoptosis
Jesenberger, V., & Jentsch, S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm731 · Cited by 355
Protein degradation and the generation of MHC class I-presented peptides
Rock, K. L., York, I. A., Saric, T., & Goldberg, A. L. (2002) · Advances in Immunology · doi:10.1016/s0065-2776(02)80012-8 · Cited by 339
An, B., Goldfarb, R. H., Siman, R., & Dou, Q. P. (1998) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400436 · Cited by 337
Daniel, K. G., Chen, D., Orlu, S., Cui, Q. C., Miller, F. R., & Dou, Q. P. (2005) · Breast Cancer Research · doi:10.1186/bcr1322 · Cited by 326
Pham, L. V., Tamayo, A. T., Yoshimura, L. C., Lo, P., & Ford, R. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.1.88 · Cited by 320
Mechanisms of proteasome inhibitor action and resistance in cancer
McConkey, D. J., & Zhu, K. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.08.002 · Cited by 309
Proteasome Inhibitors Activate Stress Kinases and Induce Hsp72
Meriin, A. B., Gabai, V. L., Yaglom, J., Shifrin, V. I., & Sherman, M. Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.11.6373 · Cited by 300
Proteasome inhibitors in cancer therapy
Crawford, L. J., Walker, B., & Irvine, A. E. (2011) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-011-0121-7 · Cited by 299
Decreased levels of proteasome activity and proteasome expression in aging spinal cord
Keller, J. N., Huang, F. F., & Markesbery, W. R. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00067-1 · Cited by 297
Inhibition of RNA polymerase II as a trigger for the p53 response
Ljungman, M., Zhang, F., Chen, F., Rainbow, A. J., & McKay, B. C. (1999) · Oncogene · doi:10.1038/sj.onc.1202356 · Cited by 288
Rideout, H. J., Larsen, K. E., Sulzer, D., & Stefanis, L. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00474.x · Cited by 274
A proteolytic system that compensates for loss of proteasome function
Glas, R., Bogyo, M., McMaster, J. S., Gaczynska, M., & Ploegh, H. L. (1998) · Nature · doi:10.1038/33443 · Cited by 270
Isotype-Specific Functions of Raf Kinases
Hagemann, C., & Rapp, U. R. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4689 · Cited by 261
Nishitani, H., Taraviras, S., Lygerou, Z., & Nishimoto, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105406200 · Cited by 254
THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY
Voorhees, P. M., & Orlowski, R. Z. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141300 · Cited by 247
Cancer cell signaling pathways targeted by spice-derived nutraceuticals
Sung, B., Prasad, S., Yadav, V. R., & Aggarwal, B. B. (2012) · Nutrition and Cancer · doi:10.1080/01635581.2012.630551 · Cited by 204
Naujokat, C., Berges, C., Höh, A., Wieczorek, H., Fuchs, D., Ovens, J., Miltz, M., Sadeghi, M., Opelz, G., & Daniel, V. (2007) · Immunology · doi:10.1111/j.1365-2567.2006.02487.x · Cited by 41
Twarog, N. R., Low, J. A., Currier, D. G., Miller, G., Chen, T., & Shelat, A. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149439 · Cited by 16
Metadata
- Authors
- Drexler, H. C. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1997-02-04
- Volume
- 94
- Issue
- 3
- Pages
- 855-860
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2117184453
- Cited by
- 481
- References
- 44
- FWCI
- 12.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.